NASDAQ:CYTXCytori Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.71 +0.08 (+4.91 %) (As of 06/3/2020 02:39 PM ET) Add Compare Share Today's Range$1.61Now: $1.71▼$1.7350-Day Range$0.20MA: $0.20▼$0.2152-Week Range$0.20Now: $1.71▼$0.75Volume25,758 shsAverage Volume915,302 shsMarket Capitalization$37.89 millionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cytori Therapeutics. Previous Next 2.9 Community Rank Outperform VotesCytori Therapeutics has received 442 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCytori Therapeutics has received 314 “underperform” votes. (Add your “underperform” vote.)Community SentimentCytori Therapeutics has received 58.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote “Outperform” if you believe CYTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCytori Therapeutics does not currently pay a dividend.Dividend GrowthCytori Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytori Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.66% of the stock of Cytori Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 2.62% of the stock of Cytori Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCytori Therapeutics has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CYTX Previous Symbol CUSIP23283K10 CIK1095981 Webwww.cytori.com Phone858-458-0900Debt Debt-to-Equity Ratio0.39 Current Ratio0.46 Quick Ratio0.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.67 million Price / Sales10.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book4.89Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-12,630,000.00 Net Margins-242.60% Return on Equity-272.70% Return on Assets-56.23%Miscellaneous Employees37 Outstanding Shares22,160,000Market Cap$37.89 million Next Earnings DateN/A OptionableOptionable Receive CYTX News and Ratings via Email Sign-up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions How were Cytori Therapeutics' earnings last quarter? Cytori Therapeutics Inc (NASDAQ:CYTX) released its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company earned $0.70 million during the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative return on equity of 272.70%. View Cytori Therapeutics' earnings history. When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work? Cytori Therapeutics shares reverse split on the morning of Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split. Has Cytori Therapeutics been receiving favorable news coverage? News headlines about CYTX stock have trended somewhat positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cytori Therapeutics earned a news impact score of 1.7 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View the latest news aboutCytori Therapeutics. Who are some of Cytori Therapeutics' key competitors? Some companies that are related to Cytori Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Cytori Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), Exelixis (EXEL), Athersys (ATHX), BCE (BCE), Synergy Pharmaceuticals (SGYP), Novavax (NVAX) and Celldex Therapeutics (CLDX). Who are Cytori Therapeutics' key executives? Cytori Therapeutics' management team includes the following people: Marc H. Hedrick, President, Chief Executive Officer & DirectorGary S. Titus, Chief Financial OfficerMark T. Marino, Chief Medical Officer & Senior Vice PresidentJohn K. Fraser, Chief ScientistRuss Havranek, VP-Global Marketing & Business Development What is Cytori Therapeutics' stock symbol? Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX." What is Cytori Therapeutics' stock price today? One share of CYTX stock can currently be purchased for approximately $1.71. How big of a company is Cytori Therapeutics? Cytori Therapeutics has a market capitalization of $37.89 million and generates $3.67 million in revenue each year. Cytori Therapeutics employs 37 workers across the globe. What is Cytori Therapeutics' official website? The official website for Cytori Therapeutics is www.cytori.com. How can I contact Cytori Therapeutics? Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
